{"id":"W7115022452","doi":"10.51731/cjht.2025.1304","title":"Nivolumab Plus Ipilimumab (Opdivo Plus Yervoy)","year":2025,"lang":"","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Durvalumab; Nivolumab; Ipilimumab; Sorafenib; Lenvatinib; Immunotherapy; Clinical trial; Sunitinib","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004845883,0.0002645734,0.0004338854,0.0004287989,0.0001655337,0.0005631953,0.000327934,0.0003119614,0.005216744],"category_scores_gemma":[0.0003451005,0.0001092555,0.0006810961,0.000316205,0.0001549073,0.0003686513,0.0003891532,0.0008178638,0.00156605],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001137604,"about_ca_system_score_gemma":0.0009344181,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004752853,"about_ca_topic_score_gemma":0.01498753,"domain_scores_codex":[0.9998035,0.00004054375,0.00001941945,0.00003593677,0.00005825486,0.00004231645],"domain_scores_gemma":[0.9999217,0.00001139823,0.00001921144,0.00000598527,0.00002102285,0.00002071709],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00399195,0.0003124089,0.00298963,0.002967864,0.0005635297,0.0002868273,0.00003923335,0.001097559,0.0180276,0.002358352,0.03856223,0.9288027],"study_design_scores_gemma":[0.006881807,0.004832184,0.01622453,0.001575815,0.0009035744,0.003354602,0.00006592738,0.001303646,0.02263097,0.001328086,0.9408506,0.00004820761],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.2167123,0.5888763,0.008912344,0.007473863,0.002625734,0.002112142,0.007273433,0.001453274,0.1645606],"genre_scores_gemma":[0.7874053,0.1318943,0.0126897,0.00602385,0.0005241396,0.0009093878,0.01078157,0.000117833,0.04965387],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.005216744,"threshold_uncertainty_score":0.01745176,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06552939086128179,"score_gpt":0.2857896053217157,"score_spread":0.2202602144604339,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}